Natural history observations in moderate aortic stenosis.
Aged
Aged, 80 and over
Aortic Valve
/ diagnostic imaging
Aortic Valve Stenosis
/ diagnostic imaging
Comorbidity
Disease Progression
Echocardiography, Doppler
Female
Heart Failure
/ diagnostic imaging
Hospitalization
Humans
Longitudinal Studies
Male
Progression-Free Survival
Retrospective Studies
Risk Assessment
Risk Factors
Severity of Illness Index
Stroke Volume
Time Factors
Ventricular Dysfunction, Left
/ diagnostic imaging
Ventricular Function, Left
Aortic stenosis
Aortic valve replacement
Moderate
Outcomes
Survival
Journal
BMC cardiovascular disorders
ISSN: 1471-2261
Titre abrégé: BMC Cardiovasc Disord
Pays: England
ID NLM: 100968539
Informations de publication
Date de publication:
19 02 2021
19 02 2021
Historique:
received:
09
10
2020
accepted:
02
02
2021
revised:
30
01
2021
entrez:
20
2
2021
pubmed:
21
2
2021
medline:
5
10
2021
Statut:
epublish
Résumé
The natural history of patients with moderate aortic stenosis (AS) is poorly understood. We aimed to determine the long-term outcomes of patients with moderate AS. We examined patients with moderate AS defined by echocardiography in our healthcare system, and performed survival analyses for occurrence of death, heart failure (HF) hospitalization, and progression of AS, with accounting for symptoms, left ventricular dysfunction, and comorbidities. We examined 729 patients with moderate AS (median age, 76 years; 59.9 % men) with a median follow-up of 5.0 years (interquartile range: 2.0 to 8.1 years). The 5-year overall survival was 52.3 % (95 % confidence interval [CI]: 48.6 % to 56.0 %) and survival free of death or HF hospitalization was 43.2 % (95 % CI: 39.5 % to 46.9 %). Worse New York Heart Association (NYHA) functional class was associated with poor long-term survival, with mortality rates ranging from 7.9 % (95 % CI: 6.6-9.2 %) to 25.2 % (95 % CI: 20.2-30.3 %) per year. Among patients with minimal or no symptoms, no futility markers, and preserved left ventricular function, 5-year overall survival was 71.9 % (95 % CI: 66.4-77.4 %) and survival free of death or HF hospitalization was 61.4 % (95 % CI: 55.5-67.3 %). Risk factors associated with adverse events were age, NYHA class, low ejection fraction and high aortic valve velocity (all p < 0.05). Patients with moderate AS are at significant risk of death. Our findings highlight the need for more study into appropriate therapeutic interventions to improve the prognosis of these patients.
Sections du résumé
BACKGROUND
The natural history of patients with moderate aortic stenosis (AS) is poorly understood. We aimed to determine the long-term outcomes of patients with moderate AS.
METHODS
We examined patients with moderate AS defined by echocardiography in our healthcare system, and performed survival analyses for occurrence of death, heart failure (HF) hospitalization, and progression of AS, with accounting for symptoms, left ventricular dysfunction, and comorbidities.
RESULTS
We examined 729 patients with moderate AS (median age, 76 years; 59.9 % men) with a median follow-up of 5.0 years (interquartile range: 2.0 to 8.1 years). The 5-year overall survival was 52.3 % (95 % confidence interval [CI]: 48.6 % to 56.0 %) and survival free of death or HF hospitalization was 43.2 % (95 % CI: 39.5 % to 46.9 %). Worse New York Heart Association (NYHA) functional class was associated with poor long-term survival, with mortality rates ranging from 7.9 % (95 % CI: 6.6-9.2 %) to 25.2 % (95 % CI: 20.2-30.3 %) per year. Among patients with minimal or no symptoms, no futility markers, and preserved left ventricular function, 5-year overall survival was 71.9 % (95 % CI: 66.4-77.4 %) and survival free of death or HF hospitalization was 61.4 % (95 % CI: 55.5-67.3 %). Risk factors associated with adverse events were age, NYHA class, low ejection fraction and high aortic valve velocity (all p < 0.05).
CONCLUSIONS
Patients with moderate AS are at significant risk of death. Our findings highlight the need for more study into appropriate therapeutic interventions to improve the prognosis of these patients.
Identifiants
pubmed: 33607944
doi: 10.1186/s12872-021-01901-1
pii: 10.1186/s12872-021-01901-1
pmc: PMC7893941
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
108Références
J Am Coll Cardiol. 2019 Oct 15;74(15):1851-1863
pubmed: 31491546
J Am Coll Cardiol. 2020 May 19;75(19):2446-2458
pubmed: 32408979
JACC Cardiovasc Imaging. 2020 Jun;13(6):1449-1450
pubmed: 32199839
Circ Cardiovasc Imaging. 2020 Apr;13(4):e009958
pubmed: 32268808
JACC Cardiovasc Interv. 2019 Apr 8;12(7):684-686
pubmed: 30878476
J Am Coll Cardiol. 2011 Jan 18;57(3):253-69
pubmed: 21216553
J Am Soc Echocardiogr. 2017 Apr;30(4):372-392
pubmed: 28385280
Am Heart J. 2016 Dec;182:80-88
pubmed: 27914503
J Am Heart Assoc. 2019 Mar 19;8(6):e011036
pubmed: 30841771
J Am Coll Cardiol. 2017 May 16;69(19):2383-2392
pubmed: 28494976
Eur Heart J. 2016 Jul 21;37(28):2276-86
pubmed: 26787441
JACC Cardiovasc Interv. 2019 Nov 11;12(21):2145-2154
pubmed: 31699376
J Thorac Cardiovasc Surg. 2013 Jun;145(6):1550-3
pubmed: 22664178
Eur Heart J. 2017 Sep 21;38(36):2739-2791
pubmed: 28886619
J Am Coll Cardiol. 2012 Oct 9;60(15):1438-54
pubmed: 23036636
JACC Cardiovasc Interv. 2019 Jan 28;12(2):196-204
pubmed: 30678799
Am J Cardiol. 2018 Sep 1;122(5):851-858
pubmed: 30037422
J Am Coll Cardiol. 2014 Jun 10;63(22):2438-88
pubmed: 24603192
Circ Cardiovasc Interv. 2018 Dec;11(12):e007220
pubmed: 30562084
J Am Heart Assoc. 2019 Apr 2;8(7):e011504
pubmed: 30897991
Circulation. 2014 Jan 14;129(2):244-53
pubmed: 24421359
J Am Coll Cardiol. 2017 Apr 4;69(13):1755-1756
pubmed: 28359524
J Am Coll Cardiol. 2020 Jan 28;75(3):304-316
pubmed: 31976869
JACC Cardiovasc Interv. 2014 Jul;7(7):707-16
pubmed: 24954571
JAMA Cardiol. 2018 Nov 1;3(11):1060-1068
pubmed: 30285058
Am J Cardiol. 1986 Feb 15;57(6):450-8
pubmed: 2936235
Circ Cardiovasc Imaging. 2018 Jun;11(6):e007451
pubmed: 29914867
Lancet. 2006 Sep 16;368(9540):1005-11
pubmed: 16980116